Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-03-05 / Cancers (Basel) 2019 Mar;11(3)Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
/in Acute Leukemia, Dendritic Cells, International Publications /von 2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution